This book addresses a profound deficiency in the field of vaccine research and development, namely the lack of a single volume describing the design and construction of vaccine strategies from first principles to implementation. This is an authoritative textbook that details a comprehensive and systematic approach to the science of vaccinology focusing on not only basic science, but the many stages required to commercialize and navigate the regulatory requirements for human application both in the United States and Europe. The book has broad appeal to clinicians, scientific and medical researchers alike, and graduate students.
show more 
show less
| |
| |
| List of Contributors | |
| |
| |
| Preface | |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Concept and Scope of Modern Vaccines | |
| |
| |
| |
| |
| Principles of Vaccine Design | |
| |
| |
| |
| Strategies to Stimulate Innate Immunity for Designing Effective Vaccine Adjuvants | |
| |
| |
| |
| |
| Antigen Processing and Presentation by MHC Class I, II, and Nonclassical Molecules | |
| |
| |
| |
| |
| Understanding the Mucosal Immune System for Better Mucosal Vaccine Design | |
| |
| |
| |
| |
| Immunologic Memory: T Cells in Humans | |
| |
| |
| |
| |
| Immunologic Memory: B cells | |
| |
| |
| |
| |
| Utility of Mouse Models in Vaccine Design and Development | |
| |
| |
| |
| |
| Utility of Nonhuman Primate Models for Vaccines | |
| |
| |
| |
| |
| Antigen Discovery | |
| |
| |
| |
| Sequence-Based Computational Approaches to Vaccine Discovery and Design | |
| |
| |
| |
| |
| Antigen Discovery for Vaccines Using High-throughput Proteomic Screening Technologies | |
| |
| |
| |
| |
| Phage Libraries | |
| |
| |
| |
| |
| Antigen Engineering | |
| |
| |
| |
| Attenuated Bacterial Vaccines | |
| |
| |
| |
| |
| Virus-like Particles as Antigen Scaffolds | |
| |
| |
| |
| |
| Recombinant MVA vaccines: Optimization, Preclinical, and Product Development | |
| |
| |
| |
| |
| Recombinant Adenoviruses for Vaccination | |
| |
| |
| |
| |
| Recombinant Avipoxviruses | |
| |
| |
| |
| |
| Intracellular Facultative Bacterial Vectors for Cancer Immunotherapy | |
| |
| |
| |
| |
| Nucleic Acid Vaccination | |
| |
| |
| |
| |
| Artificial Antigen-presenting Cells: Large Multivalent Immunogens | |
| |
| |
| |
| |
| Delivery Systems | |
| |
| |
| |
| Transcutaneous Immunization via Vaccine Patch Delivery System | |
| |
| |
| |
| |
| Needle-free Jet Injection for Vaccine Administration | |
| |
| |
| |
| |
| Oral Vaccines: An Old Need and Some New Possibilities | |
| |
| |
| |
| |
| Adjuvants: From Serendipity to Rational Discovery | |
| |
| |
| |
| |
| Immunostimulatory Properties of Biodegradable Microparticles | |
| |
| |
| |
| |
| Co-administration of Co-stimulatory Moieties | |
| |
| |
| |
| |
| Toll Receptors in Relation to Adjuvant Effects | |
| |
| |
| |
| |
| Regulatory Considerations | |
| |
| |
| |
| Regulatory Issues (FDA and EMA) | |
| |
| |
| |
| |
| Evaluating Vaccine Efficacy | |
| |
| |
| |
| Immune Monitoring Design within the Developmental Pipeline for an Immunotherapeutic or Preventive Vaccine | |
| |
| |
| |
| |
| Clinical Development Strategy: Nuts and Bolts | |
| |
| |
| |
| |
| Current Approaches to Identify and Evaluate Cancer Biomarkers for Patient Stratification | |
| |
| |
| |
| |
| Implementing Immunizations/Therapies | |
| |
| |
| |
| Mass Immunization Strategies | |
| |
| |
| |
| |
| The Role of Mathematical Models in Vaccine Development and Public Health Decision Making | |
| |
| |
| |
| |
| Vaccine Safety | |
| |
| |
| |
| Index | |
W. John W. Morrow, PhD, DSc, FRCPath, Principal Scientist, Director of New Technology and Prinicpal Scientist, InBios, and Professor, Department of PathoBiology, University of Washington, Seattle, USAClint Schmidt, PhD, Immunotherapy Scientist, Dendreon Corporation, Seattle, Washington, USANadeem Sheikh, PhD, Immunotherapy Scientist, Dendreon Corporation, Seattle, Washington, USA
W. John W. Morrow, PhD, DSc, FRCPath, Principal Scientist, Director of New Technology and Prinicpal Scientist, InBios, and Professor, Department of PathoBiology, University of Washington, Seattle, USAClint Schmidt, PhD, Immunotherapy Scientist, Dendreon Corporation, Seattle, Washington, USANadeem Sheikh, PhD, Immunotherapy Scientist, Dendreon Corporation, Seattle, Washington, USA
